Aditxt Revenue and Competitors

Loma Linda, CA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Aditxt's estimated annual revenue is currently $5.3M per year.(i)
  • Aditxt's estimated revenue per employee is $210,800

Employee Data

  • Aditxt has 25 Employees.(i)
  • Aditxt grew their employee count by -7% last year.

Aditxt's People

NameTitleEmail/Phone
1
Co-Founder and CIOReveal Email/Phone
2
Co-Founder, Chairman and CEOReveal Email/Phone
3
Chief M&A OfficerReveal Email/Phone
4
Chief Financial OfficerReveal Email/Phone
5
Chief Financial OfficerReveal Email/Phone
6
Chief Operating OfficerReveal Email/Phone
7
SVP, Clinical Development - TransplantationReveal Email/Phone
8
VP, Revenue OperationsReveal Email/Phone
9
VP - FinanceReveal Email/Phone
10
VP BioinformaticsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M80%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1731%N/AN/A
Add Company

What Is Aditxt?

Aditx Therapeutics, Inc. (Aditxtâ„¢) is a pre-clinical stage, life sciences company with a mission to prolong life and enhance life quality of transplanted patients. Aditxtâ„¢'s current portfolio includes an exclusive worldwide license for commercializing Apoptotic DNA Immunotherapyâ„¢ (ADiâ„¢), which utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues.

keywords:N/A

N/A

Total Funding

25

Number of Employees

$5.3M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Aditxt News

2022-04-17 - Aditxt, Inc. Partners with Guthy-Renker Affiliate GRS to Launch ...

Aditxt is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system.

2022-04-06 - Aditxt Signs Revenue-Sharing Agreement with Cellvera for up ...

Aditxt is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt's immune mapping...

2022-03-22 - Aditxt to Participate in the 2022 Virtual Growth Conference

Aditxt is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.3M25-7%N/A
#2
$2.2M26-7%N/A
#3
$3.7M330%N/A
#4
$8M37-10%N/A
#5
$10.6M497%N/A